Effectiveness of an absorbable fibrin sealant patch to reduce lymphoceles formation after axillary lymphadenectomy for breast cancer: a matched-pair analysis.

Abstract

BACKGROUND:

This study evaluated the use of TachoSil as an adjunctive therapy for reducing axillary lymphocele formation.

METHODS:

Eighty-six patients diagnosed with breast cancer N+ and treated with axillary lymphadenectomy received a TachoSil patch in the axillary wound. Using a database of patients without placing a hemostatic patch, we applied a matched case-control in a 1-to-2 fashion. Multiple and logistic regression analyses were used to evaluate postoperative results.

RESULTS:

Patient group with TachoSil showed a significantly lower drainage volume (P < .001) and the length of stay was significantly shorter (P < .001). The number of patients with evacuative punctures was 24.5% in the group with patch versus 51.2% in the control group (P < .001). In multivariate analysis, the use of TachoSil was a significant predictor of reducing axillary drainage volume (P < .001), mean length of hospital stay (P = .001), and number of evacuative punctures of lymphocele (odds ratio .264, 95% confidence interval .144 to .484, P < .001).

CONCLUSION:

The use of TachoSil in axillary lymphadenectomy may be a safe and useful treatment option for reducing axillary drainage volume, incidence of symptomatic lymphocele, and hospital stay.

• Authors: Elena Navarro-Rodríguez, Irene Gómez-Luque, Nélida Díaz-Jiménez, Pilar Rioja-Torres, Guillermo Bascuñana-Estudillo, Juan Francisco Ruiz-Rabelo, Rubén Ciria-Bru, Marina Álvarez-Benito, Sebastián Rufián-Peña, Javier Briceño-Delgado
• Journal: American journal of surgery (Am J Surg) Vol. 208 Issue 5 Pg. 824-830 (Nov 2014) ISSN: 1879-1883 [Electronic] United States
• PMID: 24881016 (Publication Type: Clinical Trial, Journal Article)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• Drug Combinations
• Fibrin Tissue Adhesive
• TachoSil
• Fibrinogen
• Thrombin

Topics

• Adenocarcinoma (surgery)
• Adult
• Aged
• Aged, 80 and over
• Axilla
• Breast Neoplasms (surgery)
• Carcinoma, Ductal, Breast (surgery)
• Carcinoma, Lobular (surgery)
• Drug Combinations
• Female
• Fibrin Tissue Adhesive (therapeutic use)
• Fibrinogen (therapeutic use)
• Humans
• Logistic Models
• Lymph Node Excision (methods)
• Lymphocele (etiology, prevention & control)
• Matched-Pair Analysis
• Middle Aged
• Multivariate Analysis
• Postoperative Complications (prevention & control)
• Thrombin (therapeutic use)
• Treatment Outcome